Sign in

Trial result ·

Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomized, multiarm, run-in phase trial.

Written based on 1 research study on PubMed, searched on 3 Nov 2026.

What was studied

This trial tested a vitamin D receptor (VDR) agonist, paricalcitol, with chemotherapy. The cancer was metastatic pancreatic cancer. All got gemcitabine and albumin-bound paclitaxel (GA). Patients were split by chance into groups. One got GA plus placebo. One got GA plus paricalcitol by vein. One got GA plus oral paricalcitol. Tumor biopsies were taken before and during treatment. The main goal was safety.

What they found

Paricalcitol was given safely with GA. Some patients on oral paricalcitol had grade 2-4 hypercalcemia. They needed lower doses. VDR was present in tumor, immune and stromal cells, at varied levels. On-treatment biopsies had fewer αSMA+ fibroblasts. The fibroblast VDR signature changed. CD8+ T cells sat denser near tumor cells in the paricalcitol arms. VDR level predicted tumor response in those arms.

What it means for patients

The authors say paricalcitol can be given safely with chemotherapy. They say the biopsies show a favourable shift in the tumor setting. They say this fits what animal models predicted.

Why it is not certain yet

This was a run-in phase trial. Its main goal was safety, not survival. The abstract does not report survival or response rates. Oral paricalcitol led to high calcium in some patients. The groups were small.

The registered trial

The paper names this trial from a public trial registry. Its page shows who the trial is for, its sites and its status.

Source

Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomized, multiarm, run-in phase trial.

PubMed · PMID 42185478

We restate facts from the source record in our own words. The original wording belongs to its publisher.

This page is not medical advice. Talk to your doctor about your own care.

Back to Pancreatic cancer publications